Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy
Authors:
Open Access
- 1 January 2017
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 7 (18) , 4383-4398
Abstract
Poor distribution of antigen/adjuvant to target sites and inadequate induction of T cell responses remain major challenges in cancer immunotherapy because of the lack of appropriate delivery systems. Nanocarrier-based antigen delivery systems have emerged as an innovative strategy to improve vaccine efficacy. Here we present polymeric hybrid micelles (PHMs) as a simple and potent antigen/adjuvant co-delivery system with highly tunable properties. PHMs consist of two amphiphilic diblock copolymers, polycaprolactone-polyethylenimine (PCL-PEI) and polycaprolactone-polyethyleneglycol (PCL-PEG). PHMs with different proportions of cationic PCL-PEI were prepared and loaded with tyrosinase-related protein 2 (Trp2) peptide and adjuvant CpG oligodeoxynucleotide to generate the Trp2/PHM/CpG co-delivery system. Lymphatic and intracellular antigen delivery as a function of PCL-PEI proportion was evaluated in vitro and in vivo. PHMs containing 10% (w/w) PCL-PEI (Trp2/PHM10/CpG) showed the optimal balance of good distribution to lymph nodes, strong immunization effect after subcutaneous administration, and low toxicity to dendritic cells. In a mouse model of B16F10 melanoma, Trp2/PHM10/CpG showed significantly higher antigen-specific cytotoxic T lymphocyte activity and greater anticancer efficacy than Trp2/PHM0/CpG without PCL-PEI or a mixture of free Trp2 and CpG. These results provide new insights into how cationic segments affect the efficiency of antigen delivery by cationic nanocarriers. They also suggest that PHMs can serve as a structurally simple and highly tunable platform for co-delivery of antigen and adjuvant in cancer immunotherapy.Keywords
This publication has 38 references indexed in Scilit:
- Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cellsImmunology & Cell Biology, 2013
- pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory OligonucleotidesACS Nano, 2013
- Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen deliveryBiomaterials, 2011
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma PatientsJournal of Immunotherapy, 2008
- Deliberately provoking local inflammation drives tumors to become their own protective vaccine siteInternational Immunology, 2008
- Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cellsProceedings of the National Academy of Sciences, 2008
- Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunityVaccine, 2008
- Therapeutic potential of Toll-like receptor 9 activationNature Reviews Drug Discovery, 2006
- Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasiaVaccine, 2004
- Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.Journal of Experimental Medicine, 1991